262 related articles for article (PubMed ID: 9644298)
1. Effect of discontinuing prophylaxis with norfloxacin in patients with hematologic malignancies and severe neutropenia. A matched case-control study of the effect on infectious morbidity.
Martino R; Subira M; Altés A; López R; Sureda A; Domingo-Albós A; Pericas R; Brunet S
Acta Haematol; 1998; 99(4):206-11. PubMed ID: 9644298
[TBL] [Abstract][Full Text] [Related]
2. Fluoroquinolone resistance of Escherichia coli at a cancer center: epidemiologic evolution and effects of discontinuing prophylactic fluoroquinolone use in neutropenic patients with leukemia.
Kern WV; Klose K; Jellen-Ritter AS; Oethinger M; Bohnert J; Kern P; Reuter S; von Baum H; Marre R
Eur J Clin Microbiol Infect Dis; 2005 Feb; 24(2):111-8. PubMed ID: 15714332
[TBL] [Abstract][Full Text] [Related]
3. Quinolone-based antibacterial chemoprophylaxis in neutropenic patients: effect of augmented gram-positive activity on infectious morbidity. National Cancer Institute of Canada Clinical Trials Group.
Bow EJ; Mandell LA; Louie TJ; Feld R; Palmer M; Zee B; Pater J
Ann Intern Med; 1996 Aug; 125(3):183-90. PubMed ID: 8686975
[TBL] [Abstract][Full Text] [Related]
4. Impact of fluoroquinolone prophylaxis on reduced infection-related mortality among patients with neutropenia and hematologic malignancies.
Reuter S; Kern WV; Sigge A; Döhner H; Marre R; Kern P; von Baum H
Clin Infect Dis; 2005 Apr; 40(8):1087-93. PubMed ID: 15791505
[TBL] [Abstract][Full Text] [Related]
5. [Prophylaxis with fluoroquinolones in patients with neutropenia].
Brodsky AL; Minissale CJ; Melero MJ; Sánchez Avalos JC
Medicina (B Aires); 1993; 53(5):401-7. PubMed ID: 8201928
[TBL] [Abstract][Full Text] [Related]
6. Ciprofloxacin prophylaxis in patients with acute leukemia and granulocytopenia in an area with a high prevalence of ciprofloxacin-resistant Escherichia coli.
Gomez L; Garau J; Estrada C; Marquez M; Dalmau D; Xercavins M; Martí JM; Estany C
Cancer; 2003 Jan; 97(2):419-24. PubMed ID: 12518366
[TBL] [Abstract][Full Text] [Related]
7. Clinical and microbiological impact of discontinuation of fluoroquinolone prophylaxis in patients with prolonged profound neutropenia.
Verlinden A; Jansens H; Goossens H; van de Velde AL; Schroyens WA; Berneman ZN; Gadisseur AP
Eur J Haematol; 2014 Oct; 93(4):302-8. PubMed ID: 24750350
[TBL] [Abstract][Full Text] [Related]
8. Tosulfloxacin versus norfloxacin for prevention of infections in chemotherapy-induced neutropenic patients.
Mori S; Ohashi K; Akiyama H; Shoji H; Sato H; Tanikawa S; Sakamaki H; Onozawa Y
Kansenshogaku Zasshi; 1994 Jul; 68(7):872-8. PubMed ID: 8089554
[TBL] [Abstract][Full Text] [Related]
9. Prevention of bacterial infection in neutropenic patients with hematologic malignancies. A randomized, multicenter trial comparing norfloxacin with ciprofloxacin. The GIMEMA Infection Program. Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto.
Ann Intern Med; 1991 Jul; 115(1):7-12. PubMed ID: 2048868
[TBL] [Abstract][Full Text] [Related]
10. [Fluoroquinolone prophylaxis utility during chemotherapy-induced severe neutropenia in patients with acute leukemia, with fluoroquinolone resistance high prevalence, in a reference hospital in Mexico City].
Ugarte-Torres A; Villasis-Keever A; Hernández-Bribiesca ME; Crespo-Solis E; Ruiz-Palacios GM; Sifuentes-Osornio J; Ponce-De-León-Garduño A
Rev Invest Clin; 2006; 58(6):547-54. PubMed ID: 17432285
[TBL] [Abstract][Full Text] [Related]
11. Norfloxacin prophylaxis for neutropenic patients undergoing bone marrow transplantation.
Menichetti F; Felicini R; Bucaneve G; Aversa F; Greco M; Pasquarella C; Moretti MV; Del Favero A; Martelli MF
Bone Marrow Transplant; 1989 Sep; 4(5):489-92. PubMed ID: 2790326
[TBL] [Abstract][Full Text] [Related]
12. Prophylactic co-trimoxazole versus norfloxacin in neutropenic children--perspective randomized study.
Cruciani M; Concia E; Navarra A; Perversi L; Bonetti F; Aricò M; Nespoli L
Infection; 1989; 17(2):65-9. PubMed ID: 2654019
[TBL] [Abstract][Full Text] [Related]
13. Comparison of norfloxacin and pefloxacin in the prophylaxis of bacterial infection in neutropenic cancer patients.
D'Antonio D; Iacone A; Fioritoni G; Betti S; Dell'Isola M; Quaglietta AM; Accorsi P; Pantalone V; Recchia A; Piergallini A
Drugs Exp Clin Res; 1992; 18(4):141-6. PubMed ID: 1451644
[TBL] [Abstract][Full Text] [Related]
14. Clinical impact of fluoroquinolone prophylaxis in neutropenic patients with hematological malignancies.
Chong Y; Yakushiji H; Ito Y; Kamimura T
Int J Infect Dis; 2011 Apr; 15(4):e277-81. PubMed ID: 21324723
[TBL] [Abstract][Full Text] [Related]
15. Infections caused by Escherichia coli resistant to norfloxacin in hospitalized cirrhotic patients.
Ortiz J; Vila MC; Soriano G; Miñana J; Gana J; Mirelis B; Novella MT; Coll S; Sábat M; Andreu M; Prats G; Solá R; Guarner C
Hepatology; 1999 Apr; 29(4):1064-9. PubMed ID: 10094947
[TBL] [Abstract][Full Text] [Related]
16. Emergence of quinolone-resistant Escherichia coli bacteremia in neutropenic patients with cancer who have received prophylactic norfloxacin.
Carratalá J; Fernández-Sevilla A; Tubau F; Callis M; Gudiol F
Clin Infect Dis; 1995 Mar; 20(3):557-60; discussion 561-3. PubMed ID: 7756475
[TBL] [Abstract][Full Text] [Related]
17. Norfloxacin vs ceftriaxone in the prophylaxis of infections in patients with advanced cirrhosis and hemorrhage.
Fernández J; Ruiz del Arbol L; Gómez C; Durandez R; Serradilla R; Guarner C; Planas R; Arroyo V; Navasa M
Gastroenterology; 2006 Oct; 131(4):1049-56; quiz 1285. PubMed ID: 17030175
[TBL] [Abstract][Full Text] [Related]
18. [Clinical study on fluoroquinolone prophylaxis in neutropenia patients with acute leukemia].
Qin TJ; Mi YC; Feng SZ; Li DP; Wei JL; Yang DL; Han MZ; Wang JX; Bian SG
Zhonghua Yi Xue Za Zhi; 2007 May; 87(20):1389-93. PubMed ID: 17785058
[TBL] [Abstract][Full Text] [Related]
19. Bacteremia due to multiresistant gram-negative bacilli in neutropenic cancer patients: a case controlled study.
Krcméry V; Spanik S; Krupova I; Trupl J; Kunova A; Smid M; Pichnova E
J Chemother; 1998 Aug; 10(4):320-5. PubMed ID: 9720472
[TBL] [Abstract][Full Text] [Related]
20. Perils of quinolone exposure in cancer patients: breakthrough bacteremia with multidrug-resistant organisms.
Rangaraj G; Granwehr BP; Jiang Y; Hachem R; Raad I
Cancer; 2010 Feb; 116(4):967-73. PubMed ID: 20052728
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
